MJM Betterment MJM Betterment
← Back to Educational Blog
News & Studies

The Breakthrough Isn't the Finish Line: What New Psilocybin Research Says About Coming Home

Before anything else: MJM Betterment does not provide, arrange, refer for, or advise on psychedelics or psychedelic-assisted therapy. Psilocybin is a Schedule I controlled substance under U.S. federal law and is illegal outside approved research. This post is about research only.

I started down this road reading about psychedelic-assisted psychotherapy, and one pattern kept jumping off the page. People would have a life-changing experience. A few weeks later, their own mind would talk them out of it: I was just high. The lesson gets filed away, and life goes back to the same old tracks.

Three new pieces of research landed in the last two months, and all three circle that same problem.

The headline: a big signal, with a big asterisk

In August, Nature Medicine published a trial from King’s College London and the South London and Maudsley NHS Foundation Trust (Rucker et al., 2026). Sixty adults with treatment-resistant depression were randomly given either a single 25 mg dose of psilocybin or a placebo. Both groups also got preparation, support on the dosing day, and follow-up integration visits at 1 day, 1 week, 3 weeks and 6 weeks.

On a clinician-rated depression scale called the MADRS, the psilocybin group scored about 10 points lower than the placebo group at week 3 (an adjusted difference of −10.41), and the gap was still there at week 6. The authors note that part of that gap came from the placebo group barely improving at all.

Here’s the honest part. It was a feasibility trial, designed to test whether a larger study could work. The blinding didn’t hold up. Of the participants asked, all 13 in the psilocybin group and 7 of 10 in the placebo group correctly guessed which one they got. The authors say plainly that expectation likely explains some of the difference, and they call for a larger confirmatory trial.

So it’s a strong signal, but it’s not a verdict.

The question underneath: is it the drug, or what happens after?

On October 5, Swedish researchers posted a preprint, which means it hasn’t been peer-reviewed yet (Kjellgren et al., Research Square). They interviewed the 9 therapists who supported participants in a placebo-controlled psilocybin trial for depression. The therapists felt the experience opened a door for therapeutic work. But the authors are careful to say that current research has yet to determine whether that psychological support is essential, and what its best structure would be.

That’s the open question in this whole field. And it’s the question we care about most.

The rabbit hole: why the old self snaps back

In August, two researchers published a framework paper in Frontiers in Psychiatry (Back & Bosnak, 2026) that names something I’ve been trying to put into words for a long time.

Their argument goes like this. Many participants in their own psilocybin trials, people living with cancer, describe their sessions as vivid and felt in the body, often hard to put into words. But most integration afterward is talk: journaling, telling the story, finding the meaning. The authors call that a potential mismatch. The experience happens in one language, and we ask people to process it in another, so part of it may get lost.

They lean on a model called REBUS (“relaxed beliefs under psychedelics”). The idea is that the brain normally runs on strong top-down predictions, its habits of mind, and the experience temporarily loosens them. My read, not theirs: when those predictions snap back, the old story about who you are can snap back with them.

That’s the “scared ego” I keep talking about. It hasn’t been shown that the new version of you is safe, so it drags you back to the familiar trail. Picture fresh mountain snow covering the old ski tracks. For a while, a new route is possible. Then everyone starts skiing the old line again.

Their proposed method, the DREAM protocol, has a trained facilitator guide patients back into the felt memory of the experience. Patients finish with a “touchstone,” a body-level anchor they’re asked to revisit for a few minutes twice a day. It’s a clinician-run research protocol, not something to try on your own.

The important caveat: this is a hypothesis-generating paper. The authors say plainly that the approach’s therapeutic efficacy has not been established. Their first feasibility pilot has 10 patients, and it’s still underway.

Someone is testing the group version

A trial at University Health Network in Toronto (NCT07737990), with an estimated July 2026 start, is testing 10 group integration sessions for people who already went through psilocybin-assisted psychotherapy in earlier trials. The researchers note that no research has yet looked at whether group therapy can support psychedelic integration for people with mood disorders. Results are years away, with completion listed for 2030.

So what does this mean for a real person going home?

Here’s what I take from it. The research world is starting to agree that the experience isn’t the whole story. It still doesn’t know how much the “after” matters, or what the after should look like.

That’s the gap MJM Betterment is being built around: reintegration. That means the work of carrying a changed perspective back into the same house, the same job, the same relationships, and the same triggers, after a big change of any kind: grief, recovery, a retreat, a hard season, or one honest conversation. It has nothing to do with taking a substance.

A few non-medical things to sit with:

  • Notice the snap-back. When you catch yourself saying “that wasn’t real,” pause and ask what the lesson was.
  • Anchor it in the body, not just the story. A breath, a posture, a place you can return to.
  • Don’t do the after alone. Lean on people you trust. If something you’ve been through is weighing on you, talk with a licensed mental health professional.

If you’re in crisis or thinking about suicide, call or text 988 (U.S.).

Be Better. “Be” is the direction. “Better” is the long road.

Sources

Education only, not medical advice. Talk with a qualified clinician about your own health. MJM Betterment does not provide psychedelics or psychedelic-assisted therapy.

Disclaimer: The information provided in this educational post is intended solely for research, general knowledge, and educational purposes. It does not constitute medical diagnosis, treatment, or legal counsel. Always consult qualified healthcare professionals or legal advisors.